Xolair (omalizumab) - Roche, Novartis
Tezspire (tezepelumab-ekko) - AstraZeneca, Amgen
Nucala (mepolizumab) - GSK
Dupixent (dupilumab) - Sanofi, Regeneron
Risk of Respiratory Tract Infections with Asthma Biologics. (PubMed, J Allergy Clin Immunol Pract) - Sep 25, 2026 - "Although further studies focusing on specific pathogens and pathways are needed, asthma biologics are not associated with a higher risk of respiratory infections. Dupilumab might reduce the risk of certain respiratory tract infections." 
Journal • Asthma • Immunology • Infectious Disease • Influenza • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5
http://www.ncbi.nlm.nih.gov/pubmed/42785633
 
Sarah Al-Obaydi; Shane Stone; Taha Al-Shaikhly
 
Sep 25, 2026
 
Prev Next